Media Articles Related to Emend (Aprepitant)
New hepatitis C drugs will place strain on health care system, MD Anderson study
Source: Liver Disease / Hepatitis News From Medical News Today [2015.03.19]
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system.
Scientists opens black box on bacterial growth in cystic fibrosis lung infection
Source: Cystic Fibrosis News From Medical News Today [2014.10.22]
Researchers from the University of Copenhagen have shown for the first time how bacteria can grow directly in the lungs of Cystic fibrosis patients, giving them the opportunity to get tremendous...
Nausea and Vomiting
Source: MedicineNet Angina Specialty [2014.07.09]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 7/9/2014 12:00:00 AM
NEPA Combo for CINV Nears Approval in Europe
Source: Medscape Hematology-Oncology Headlines [2015.03.27]
In Europe, approval has been recommended for combination netupitant and palonosetron to prevent chemotherapy-induced nausea and vomiting (CINV) in cancer patients.
Published Studies Related to Emend (Aprepitant)
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and
vomiting following high-dose cisplatin in Chinese patients: a randomized,
double-blind, placebo-controlled phase III trial. 
(HEC) in Asian countries... CONCLUSIONS: The addition of aprepitant to standard antiemetic treatment regimens
Efficacy of aprepitant among patients aged 65 and over receiving moderately to
highly emetogenic chemotherapy: a meta-analysis of unpublished data from
previously published studies. 
analyses from four previously published studies... CONCLUSION: We conclude that for both the under 65years and the age 65 and over
Prevention of nausea and vomiting associated with stem cell transplant: results
of a prospective, randomized trial of aprepitant used with highly emetogenic
preparative regimens. 
Uncontrolled delayed nausea and vomiting remains a problem after high-dose
preparative regimens used for autologous and allogeneic hematopoietic stem cell
transplants. Recently, aprepitant was approved for highly and moderately
emetogenic chemotherapy, and, in particular, is effective for decreasing delayed
Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal
oxycodone in prescription opioid abusers. 
Pre-clinical studies suggest that the neurokinin-1 (NK1) receptor may modulate
the response to opioids, with NK(1) inactivation leading to decreased opioid
reinforcement, tolerance and withdrawal...
Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk
patients: a phase II randomized, double-blind placebo controlled trial. 
patients... CONCLUSIONS: Aprepitant did not lower incidence of post-ERCP pancreatitis in this
Clinical Trials Related to Emend (Aprepitant)
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3) [Recruiting]
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for
the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0
months to 17 years of age.
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial [Recruiting]
The object of this study is to evaluate the superiority of aprepitant therapy with a
5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a
5HT3-receptor antagonist and dexamethasone for prevention of nausea and vomiting in first
Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose [Recruiting]
The investigators' in vitro data suggest that Neurokinin-1 receptor antagonists like
aprepitant will decrease the expression of CCR5, an essential co-receptor in the life cycle
of HIV, in the surface of macrophages and lymphocytes to levels at least similar to those
observed in patients heterozygous for the CCR5 32 mutation. Together with a direct potential
antiviral effect this could alter disease progression in patients with HIV infection.
The investigators' hypothesis is that aprepitant is safe, tolerable and has antiviral
activity in HIV infected individuals.
This is randomized, placebo controlled, double blind study to determine the safety and
antiviral activity of aprepitant by comparing the change in HIV RNA viral load after 2 weeks
of aprepitant monotherapy.
18 HIV infected males and females â‰¥ 18 years old who have early infection with CD4 cell
counts â‰¥ 350 cells/mm3. Subjects will be randomized 1: 1 to receive 375 mg of aprepitant
(EmendÂ®) or placebo.
A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208 AM3) [Recruiting]
This study will compare the safety and efficacy of a three-day oral aprepitant regimen
(aprepitant plus ondansetron) to ondansetron alone in the prevention of chemotherapy-induced
nausea and vomiting (CINV) in the 120 hours following the initiation of chemotherapy in
Treatment of Chemotherapy-induced Nausea and Vomiting [Recruiting]
Delayed nausea is a common problem after high dose chemotherapy for bone marrow
transplantation. This study wants to compare standard prophylactic anti-emetic therapy with
the same treatment plus the drug aprepitant (Emend). The hypothesis is that addition of
Emend will reduce nausea and vomiting.
Reports of Suspected Emend (Aprepitant) Side Effects
Drug Interaction (16),
Renal Failure Acute (14),
Septic Shock (9), more >>